ENDRA Life Sciences Q3 net loss $3.1M; FDA De Novo review ongoing

ENDRA Life Sciences Inc.

Net loss $3.1M ($0.40/share) vs $3.4M ($1.09/share) in Q3 2022; operating expense $3.1M.
Cash $3.3M at Sept 30; raised $1.2M via ATM equity facility during Q3.
TAEUS De Novo submission under substantive FDA review; clinical data showed 95% sensitivity.
Achieved 70 issued patents globally; targeting first European commercial orders near-term.
Presented at major liver disease conferences; expects MASLD treatment approvals in early 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ENDRA Life Sciences Inc. reported the quarter ended September 30, 2023 results: net income Net loss in the third quarter of 2023 was $3.1 million, or $0.40 per share, EPS $0.40 per share.

Period: the quarter ended September 30, 2023
Net income: Net loss in the third quarter of 2023 was $3.1 million, or $0.40 per share
EPS: $0.40 per share
Result: reported results

Exact text from the filing

ENDRA Life Sciences Inc . (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today reports financial results for the three and nine months ended September 30, 2023 and provides a business update.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

ENDRA Life Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-014355

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.